pharmaphorum March 27, 2024
Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinical trial of AstraZeneca’s experimental therapy tralokinumab.
The e-Lung software was able to stratify patients at risk of IPF progression more effectively than standard techniques, with implications for the way subjects are enrolled into clinical trials of new therapies, according to a paper on the study published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).
The technology, which provides automated processing and interpretation of CT scans, was used in a 52-week trial of tralokinumab, an anti-IL-13 antibody that is already on the market as Adtralza for atopic dermatitis.
AZ licensed rights to the antibody...
Today's Sponsors
Today's Sponsor